TRC205 / Tracon Pharma - LARVOL DELTA

Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment (AASLD 2016) - "The clinical candidate endoglin antibody TRC205, an IgG4, also reduced NAFLD activity score (3.6 +/- 1.1) compared to vehicle control (p<0.001) with the reduction in NAFLD activity score similar to that seen with telmisartan (3.3 +/- 1.2). Endoglin antibodies inhibited CCl4 induced hepatic fibrosis and ameliorated hepatocyte injury and inflammation in the STAM model of NASH. Endoglin antibodies are being studied in multiple Phase 2 trials in oncology patients and may be applicable in fibrotic diseases."

Biosimilar • Fibrosis • Immunology • Oncology